BARICITINIB VERSUS TOCILIZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE COVID-19

被引：0
|
作者：
Lewis-Wolfson, Temeka [1 ]
Joyner, Kayla [2 ]
Reid, Nancy [1 ]
机构：
[1] Winchester Med Ctr, Winchester, VA USA
[2] Shenandoah Univ, Bernard J Dunn Sch Pharm, Winchester, VA USA
来源：
CRITICAL CARE MEDICINE | 2023年 / 51卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
409
引用
收藏
页码：191 / 191
页数：1
相关论文
共 50 条
  • [1] Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19
    Reid, Nancy Kierstin
    Joyner, Kayla Rena
    Lewis-Wolfson, Temeka Dawn
    ANNALS OF PHARMACOTHERAPY, 2023, 57 (07) : 769 - 775
  • [2] Reply: Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19
    Lewis-Wolfson, Temeka Dawn
    Joyner, Kayla Rena
    ANNALS OF PHARMACOTHERAPY, 2023, 57 (09) : 1118 - 1119
  • [3] Comment: Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19
    Mungmunpuntipantip, Rujittika
    Wiwanitkit, Viroj
    ANNALS OF PHARMACOTHERAPY, 2023, 57 (09) : 1117 - 1117
  • [4] USE OF BARICITINIB AND TOCILIZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE COVID-19 IN HOSPITALIZED PATIENTS
    Xibille Friedmann, D. X.
    Carrillo Vazquez, S. M.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 899 - 900
  • [5] Adverse Effects of Tocilizumab Versus Baricitinib in Severe COVID-19
    Leaf, David E.
    Gordon, Anthony C.
    Lawler, Patrick R.
    CRITICAL CARE MEDICINE, 2023, 51 (09) : E184 - E185
  • [6] Baricitinib or Tocilizumab? Treatment of Patients Hospitalized With Severe COVID-19
    Cawcutt, Kelly A.
    Kalil, Andre C.
    CRITICAL CARE MEDICINE, 2023, 51 (03) : 413 - 415
  • [7] Tocilizumab Versus Baricitinib for the Treatment of COVID-19 in Patients With Obesity
    Troyer, Bradley S.
    Scherrer, Nicole Kovacic
    Garavaglia, Jeffrey
    JOURNAL OF PHARMACY PRACTICE, 2024, 37 (03) : 632 - 636
  • [8] Outcomes and Adverse Effects of Baricitinib Versus Tocilizumab in the Management of Severe COVID-19*
    Peterson, Joy H.
    Paranjape, Neha S.
    Grundlingh, Nina
    Priestley, Jennifer L.
    CRITICAL CARE MEDICINE, 2023, 51 (03) : 337 - 346
  • [9] Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial
    Karampitsakos, Theodoros
    Papaioannou, Ourania
    Tsiri, Panagiota
    Katsaras, Matthaios
    Katsimpris, Andreas
    Kalogeropoulos, Andreas P.
    Malakounidou, Elli
    Zarkadi, Eirini
    Tsirikos, Georgios
    Georgiopoulou, Vasiliki
    Sotiropoulou, Vasilina
    Koulousousa, Electra
    Chourpiliadi, Charikleia
    Matsioulas, Apostolos
    Lagadinou, Maria
    Sampsonas, Fotios
    Akinosoglou, Karolina
    Marangos, Markos
    Tzouvelekis, Argyris
    CLINICAL MICROBIOLOGY AND INFECTION, 2023, 29 (03) : 372 - 378
  • [10] Tocilizumab is recommended for the treatment of severe COVID-19
    Zhou, Yonggang
    Wei, Haiming
    EBIOMEDICINE, 2020, 61
12345